Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Adjuvant Chemotherapy

GB G. S. Banipal
BS B. V. Stimec
SA S. N. Andersen
AF A. E. Faerden
BE B. Edwin
JB J. Baral
JN J. M. Nesgaard
JB J. Šaltytė Benth
DI D. Ignjatovic
ask Ask a question
Favorite

Adjuvant chemotherapy after curative resection was offered to patients under 75 years of age with stage III colon cancer, according to the Norwegian Guidelines for Colorectal Cancer21 and the German guidelines of the Program in Oncology.22 Patients between 70 and 75 years old received routine monotherapy, either 5-flurouracil (5-FU) or capecitabine (Xeloda). Patients under 70 years of age were routinely offered XELOX in case of N1 stage (6 cycles of capecitabine + oxaliplatin) or XELOX/FOLFOX/FLOX in case of N2 stage (12 cycles of either capecitabine or 5-flurouracil combined with oxaliplatin).

Stages I/II (SS1) or RS1/RS2 were routinely not given adjuvant chemotherapy treatments,21,22 with the following exceptions:

In this substudy, there were no perioperative tumor perforations or upstaging because of tumor deposits in the histopathological findings.

Copyright and License information: The Author(s) ©2022
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A